menu
    • menu
    [{"orgOrder":0,"company":"Servier Canada","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"UCART19","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Servier Canada","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Servier Canada \/ Servier Canada","highestDevelopmentStatusID":"6","companyTruncated":"Servier Canada \/ Servier Canada"},{"orgOrder":0,"company":"Servier Canada","sponsor":"Symphogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Sym021","moa":"PD1","graph1":"Oncology","graph2":"Phase I","graph3":"Servier Canada","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Servier Canada \/ Servier Canada","highestDevelopmentStatusID":"6","companyTruncated":"Servier Canada \/ Servier Canada"}]

    Find Clinical Drug Pipeline Developments & Deals by Servier Canada

    Menu

    Servier Canada

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Servier Canada

    Canada arrow
    European Coatings Show
    Not Confirmed

    Servier Canada

    Canada arrow
    European Coatings Show
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sym021

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Recipient : Symphogen

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline

    Details : Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform.

    Product Name : Undisclosed

    Product Type : Large molecule

    Upfront Cash : Undisclosed

    April 03, 2020

    Lead Product(s) : Sym021

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Recipient : Symphogen

    Deal Size : Undisclosed

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Servier Canada

    Canada arrow
    European Coatings Show
    Not Confirmed

    Servier Canada

    Canada arrow
    European Coatings Show
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : UCART19

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Recipient : Cellectis

    Deal Size : $410.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Product...

    Details : Cellectis grants to Servier an expanded exclusive worldwide license to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19.

    Product Name : Undisclosed

    Product Type : Cell and Gene therapy

    Upfront Cash : $27.6 million

    March 04, 2020

    Lead Product(s) : UCART19

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Recipient : Cellectis

    Deal Size : $410.0 million

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth